1. Home
  2. AKRO vs APLD Comparison

AKRO vs APLD Comparison

Compare AKRO & APLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • APLD
  • Stock Information
  • Founded
  • AKRO 2017
  • APLD 2001
  • Country
  • AKRO United States
  • APLD United States
  • Employees
  • AKRO N/A
  • APLD N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • APLD Investment Bankers/Brokers/Service
  • Sector
  • AKRO Health Care
  • APLD Finance
  • Exchange
  • AKRO Nasdaq
  • APLD Nasdaq
  • Market Cap
  • AKRO 2.0B
  • APLD 1.6B
  • IPO Year
  • AKRO 2019
  • APLD N/A
  • Fundamental
  • Price
  • AKRO $28.08
  • APLD $7.80
  • Analyst Decision
  • AKRO Strong Buy
  • APLD Strong Buy
  • Analyst Count
  • AKRO 8
  • APLD 7
  • Target Price
  • AKRO $46.83
  • APLD $11.29
  • AVG Volume (30 Days)
  • AKRO 594.3K
  • APLD 17.1M
  • Earning Date
  • AKRO 02-27-2025
  • APLD 01-14-2025
  • Dividend Yield
  • AKRO N/A
  • APLD N/A
  • EPS Growth
  • AKRO N/A
  • APLD N/A
  • EPS
  • AKRO N/A
  • APLD N/A
  • Revenue
  • AKRO N/A
  • APLD $189,956,000.00
  • Revenue This Year
  • AKRO N/A
  • APLD $64.99
  • Revenue Next Year
  • AKRO N/A
  • APLD $55.02
  • P/E Ratio
  • AKRO N/A
  • APLD N/A
  • Revenue Growth
  • AKRO N/A
  • APLD 124.03
  • 52 Week Low
  • AKRO $15.32
  • APLD $2.36
  • 52 Week High
  • AKRO $37.00
  • APLD $11.25
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 41.87
  • APLD 43.30
  • Support Level
  • AKRO $27.45
  • APLD $7.41
  • Resistance Level
  • AKRO $28.76
  • APLD $9.35
  • Average True Range (ATR)
  • AKRO 1.49
  • APLD 0.85
  • MACD
  • AKRO -0.12
  • APLD -0.19
  • Stochastic Oscillator
  • AKRO 17.98
  • APLD 13.64

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About APLD Applied Digital Corporation

Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments; Data Center Hosting Business, Cloud Services Business, and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business which operates data centers to provide energized space to crypto mining customers.

Share on Social Networks: